1. Human fibrinogen was subjected to proteolysis by enzyme preparations (clinical Arvin and IRC-50 Arvin) from the venom of Agkistrodon rhodostoma. 2. IRC-50 Arvin releases three peptides from fibrinogen, and these were identified as fibrinopeptides AP, AY and A. 3. The less purified 'clinical' Arvin releases, in addition to fibrinopeptides AP, AY and A, small amounts of two heptapeptides derived from fibrinopeptides AP and A, probably because it contains another enzyme as well as Arvin. 4 . No fibrinopeptide B is released by either Arvin preparation. 5. Thus, although Arvin is known to differ from 'reptilase' from Bothrops jararaca in that it does not activate the enzyme that cross-links fibrin (fibrinstabilizing factor), it is identical with reptilase with respect to the peptides that it liberates from fibrinogen.
Arvin is a purified proteolytic enzyme fraction isolated from the venom of Agkistrodon rhodostoma, the Malayan pit viper (Esnouf & Tunnah, 1967) . The preparation can be used clinically to produce controlled defibrination in patients requiring anticoagulant therapy. Unlike the usual anticoagulants it acts directly on fibrinogen, and plasma concentrations of fibrinogen can be decreased virtually to zero without apparently affecting other plasma clotting factors (Bell, Pitney & Goodwin, 1968;  Sharp, Warren, Paxton & Allington, 1968; Bell, Bolton & Pitney, 1968) .
When purified thrombin acts on human fibrinogen in vitro, four small soluble peptides (designated fibrinopeptides A, AP, AY and B; see Blombiick, Blomback, Edman & Hessel, 1966) are released and polymerization of the modified fibrinogen molecule then leads to the formation of a fibrin gel. The action of Arvin on fibrinogen also leads to the production of a fibrin gel, but in this case the gel has very different mechanical properties and is readily dispersed.
In view of the considerable clinical potential of Arvin the elucidation of the precise nature of its action on fibrinogen is desirable. The present paper describes the nature of the peptides released from fibrinogen by two Arvin preparations that differ in their degree of purification. A preliminary account of this work has already been made (Ewart, Hatton, Basford & Dodgson, 1969 Clotting offibrinogen. A 1% solution of purified fibrinogen in 0.3M-ammonium acetate adjusted to pH7.0 with aceticacid was dialysed for 20-40h against frequent changes of the same buffer before the addition of sufficient purified thrombin or Arvin to give a concentration of 1-2 units/ml.
The whole was allowed to stand at 250C for 6h when the clot was broken up and the fluid separated on a Buchner funnel. The broken clot was washed thoroughly with water, and the clot supernatant and washings were combined and freeze-dried immediately.
Desalting by gel filtration. Freeze-dried clot supernatants were dissolved in 12ml of 0.1 M-pyridine and desalted by passing through a column (940mmx 26mm) of Sephadex G-25 (medium grain). Elution was with 0.1M-pyridine. All material eluted before the salt peak was bulked and freeze-dried.
High-voltage electrophoresis. Peptides were separated on Whatman 3MM paper with 0.25M pyridine-acetic acid buffer, pH4.2 (prepared by adding acetic acid to aqueous pyridine so that the final concentration of the latter was 0.25M; other pyridine-acetic acid buffers described below were prepared in an analogous manner). A potential gradient of 5.3V/mm for 2h was employed and peptides were detected with ninhydrin reagent or the chlorinestarch-KI reagent of Rydon & Smith (1952) . Argininecontaining peptides were detected with the Sakaguchi reagent (Roche, Thoi & Hatt, 1954) and phosphatecontaining peptides with molybdate reagent after hydrolysis in 0.5m-NaOH (Bandurski & Axelrod, 1951) . Dowex 50 chromatography. Peptides present in the clot supernatants were separated by chromatography on columns of the sulphonic resin Dowex 50 (X2; 200-400 mesh) at 250C. The procedure finally adopted differs appreciably from that of Blombick et al. (1966) for fibrinopeptides liberated by thrombin, particularly with regard to the buffer systems. Two such systems were employed. With system A, material was loaded on to the column (300mmx 9mm) in 0.2x-pyridine-acetic acid buffer, pH2.5, and elution was carried out with 100ml of the same buffer, followed by 120ml of a 240ml linear gradient ofpyridine-acetic acid buffer (ranging from 0.2m-to 1.OM-pyridine and from pH2.5 to 5.0). Finally 100ml of 8.5M-pyridine-acetic acid buffer, pH5.6, was passed through the column. With system B, material was loaded on to the column (680mmx9mm) inO. 2m-pyridine-acetic acid buffer, pH3.1, and elution was carried out with 140ml of the same buffer.
Samples of the eluate fractions (4ml fractions were usually collected) were tested with the ninhydrin reagent after alkaline hydrolysis (Hirs, Moore & Stein, 1956) .
Amino acid andysi8. Peptides (approx. 0.l,umol) were hydrolysed with 6M-HCl (Iml) at 1100C in sealed evacuated tubes for 24h and the hydrolysates were then evaporated to dryness under reduced pressure. Amino acid analyses were performed with a Technicon AutoAnalyzer, modified for fast analyses with a 230mm column and a stepwise elution programmer (Locarte Co. Ltd., London S.W.7, U.K.). N-Terminal amino acid analy8i8. The DNS-chloride method (Gray & Hartley, 1963) 
RESULTS

Separation and identification of fibrinopeptide8
relewed from fibrinogen by thrombin. The action of thrombin on human fibrinogen leads to the release offour fibrinopeptides, designated A, AP, AY and B (Blomback et al. 1966) . A further peptide (believed to be peptide B lacking the C-terminal arginine) is also generally present in clot supernatants (B. Blomback, personal communication). These various peptides were separated and identified in the present study in order to provide a basis for comparison with those released by Arvin. The Dowex 50 separation method employed differed appreciably from that described by Blomback et al. (1966) , particularly with regard to buffer systems.
Human fibrinogen (1.0-1.5g portions) was clotted with thrombin for 6h and the peptides present inthe 04 Fraction no. (Fig. 1) . Fractions 6-16 were pooled, freeze-dried and rechromatographed with system B (Fig. 2) . The following fractions from these two chromatographic runs were combined: from the system A run fractions 2-4 (designated fraction T-I), 40-43 (fraction T-IV) and 44-50 (fraction T-V), and from the system B run fractions 18-24 (fraction T-II) and 26-35 (fraction T-III towards the anode were as follows: fraction T-II, 69mm; fraction T-III, 33mm; fraction T-IV, 33mm; fraction T-V, 20mm. Trace amounts of a band with mobility of 33mm could be detected in fraction T-V, reflecting the overlap of fraction T-IV with this fraction. Amino acid and N-terminal amino acid analyses (Table 1) , electrophoretic mobility and staining reactions for arginine and phosphate established that fractions T-II, T-III, T-IV and T-V were fibrinopeptides AP, B, AY and A respectively. The properties of fraction T-I indicate that it is fibrinopeptide B lacking its C-terminal arginine.
Separation and identification of the fibrinopeptides releasedfromfibrinogen by clinical Arvin. Fibrinogen (1.0-1.5g portions) was clotted with clinical Arvin for 6h and the desalted clot supernatants were subjected to Dowex 50 chromatography with system A (Fig. 3) . The following fractions were combined and freeze-dried: 3-4 (designated fraction A-I), 5-6 (fraction A-II), 7-16 (fraction A-III), 18-23 (fraction A-IV), 41-44 (fraction A-V), 45-51 (fraction A-VI) and 60-68 (fraction A-VII).
On high-voltage electrophoresis the pooled fractions, with two exceptions, gave single bands that moved towards the anode with the following mobilities: fraction A-I, 184mm; fraction A-II, 150mm; fraction A-III, 69mm; fraction A-IV, 108mm; fraction A-V, 33mm; fraction A-VI, 20mm. Trace amounts of a band with a mobility of 33mm were detected in fraction A-VI, reflecting the overlap of fraction A-V with this fraction.
Fraction A-VII moved towards the cathode but tended to streak on electrophoresis and was not homogeneous.
Amino acid and N-terminal and C-terminal case a second degradation product containing arginine was also detected, the chromatographic properties of which fell within the limits exhibited by fraction A-VII (cf. Fig. 3 ). This product was presumed to be the arginine-containing nonapeptide that would remain after liberation ofthe N-terminal heptapeptide section from either fibrinopeptide AP or fibrinopeptide A. However, this material has not yet been characterized. The heptapeptides are probably formed after the release of fibrinopeptides AP and A as they were either absent, or present only in traces, in clot supernatants obtained by incubating fibrinogen with clinical Arvin for a period of only 1 h. At that Vol. 118 607 0 V) time the release of the 'A' peptides was essentially complete. No fibrinopeptide B could be detected among the products of the action of clinical Arvin. However, the minor fraction A-I showed electrophoretic, chromatographic and staining properties consistent with it being fibrinopeptide B lacking the C-terminal arginine. The amino acid composition was very similar to that expected for this peptide but with a rather high value for glycine. This may not be significant in view of the fact that only very small quantities of this peptide were available for analysis. Further comment about this fraction is made below. Action of IRC-50 Arvin on fibrinogen. Portions of fibrinogen (1.0-1.5g) were clotted with IRC-50 Arvin for 6h and the desalted clot supernatants were subjected to Dowex 50 chromatography with system A (Fig. 4) . The following fractions were combined and freeze-dried: 7-14 (fraction PA-I), 41-44 (fraction PA-II) and 45-50 (fraction PA-III). Onhigh-voltageelectrophoresisthepooledfractions, with one exception, moved as single bands towards the anode with the following mobilities: fraction PA-I, 69mm; fraction PA-II, 33mm; fraction PA-III, 20mm. Trace amounts of a band of mobility 33mm were detected in fraction PA-III, reflecting the overlap of fraction PA-II with this fraction.
Amino acid composition, N-terminal and Cterminal amino acids, staining reactions (Table 3) , chromatographic and electrophoretic behaviour established that fractions PA-I, PA-II and PA-Ill were fibrinopeptides AP, AY and A respectively. Fibrinopeptide B was not present in these clot supernatants. Notable also was the absence of material corresponding to the heptapeptides (fractions A-II and A-IV; Fig. 3 ) and the basic material (fraction A-VII; Fig. 3 
DISCUSSION
The four fibrinopeptides released by the action of thrombin have been shown (see Blomback et al. 1966) to possess the amino acid sequences shown in Fig. 5 .
These four fibrinopeptides have all been recognized in the thrombin clot supernatants in the present work. In each case the liberation ofthe 'A' peptides and the 'B' peptide is the result of the cleavage of an arginyl-glycyl bond. In contrast, the clotting enzyme of Agki8trodon rhodostoma, referred to as IRC-50 Arvin, liberates only the 'A' peptides from fibrinogen. In this respect it appears to resemble reptilase (Blomback, 1958) , a clotting enzyme prepared from the venom of Bothrop8 jararaca. The two snake-venom enzymes thus exhibit a most remarkable specificity towards fibrinogen in that they cleave only the arginyl-glycyl bond linking the 'A' peptides to the remainder of the fibrinogen molecule. Loss of 'A' peptides only presumably leads to the production of a polymer of the type [(a,f(B) The action of clinical Arvin on fibrinogen is more complex than that of IRC-5O Arvin and this reflects the presence in the former preparation of a second proteolytic enzyme (M. W. C. Hatton, unpublished work). The action of this enzyme leads to the appearance in clot supernatants of peptides additional to the 'A'-type fibrinopeptides released by the clotting enzyme. These additional peptides are present in relatively small amounts. Evidence has been presented indicating that two of them are the acidic N-terminal heptapeptides derived from fibrinopeptides AP and A, and having the following amino acid sequences respectively: and Ala-Asp-SerP-Gly-Glu-Gly-Asp Ala-Asp-Ser-Gly-Glu-Gly-Asp
The action of clinical Arvin also leads to the appearance of basic material in the clot supernatants. This has not yet been characterized, but probably includes the nonapeptide fragment that would remain after liberation of the N-terminal heptapeptides from fibrinopeptides AP and A.
The appearance of very small amounts of an acidic peptide (believed to be fibrinopeptide B lacking the C-terminal arginine) in clot supernatants from both thrombin and clinical Arvin is rather puzzling, particularly as the latter enzyme does not release fibrinopeptide B. Minute traces of a similar Ala-Asp-Ser -Gly-GIu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val -Arg Ala-Asp-SerP-Gly-Glu -Gly -Asp-Phe-Leu-Ala-Glu -Gly -Gly-Gly-Val -Arg Asp-Ser -Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val -Arg Pyr-Gly -Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg material may also be present in IRC-50 Arvin clot supernatants (see Fig. 4 ). In our experience the material has been a consistent feature of clot supernatants from both thrombin and clinical Arvin, and Dr B. Blomback has indicated that he has also frequently noted it in clot supernatants. However, in terms of quantity, the amount present in Arvin clot supernatants is negligible compared with the amounts of the 'A' peptides that are released.
The benign action of Arvin in vivo is probably because, unlike thrombin, the enzyme does not activate fibrin-stabilizing factor (Barlow, Holleman & Lorand, 1970) . In this respect Arvin differs from reptilase as the latter enzyme has been shown to be capable of activating fibrin-stabilizing factor (Kopec, Latallo, Stahl & Wegrzynowicz, 1969) . Under these circumstances Arvin microclots formed in vivo cannot become cross-linked and are likely to be good substrates for the fibrinolytic system. However, the non-release of fibrinopeptide B may also be of importance as it is possible that the [(o,%(B)y)2]n polymer is more susceptible to the action of the fibrinolytic system than the [(OcPy)21, type. The former polymer consists of very thin filaments (Hall & Slayter, 1959) , unlike the latter where relatively thick interconnected fibres are formed.
Note added. Since submission of this paper for publication it has been noted that Holleman & Coen (1970) have published a paper in which they come to similar conclusions to those arrived at in the present paper and in our previous publication (Ewart et al. 1969 ).
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